Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
European Psychiatry November 17, 2023 Émeline Gaudré-Wattinne, Lila Mekaoui, Maud Rothärmel et al. 1 citation
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/2019 the French National Agency for Medicines and Health Product Safety granted an early access program for Esketamine nasal spray framed by a...